Shattuck Q3 Loss Widens to $25.2M as SL-325 Phase 2b Crohn's Trial Begins
STTK has more than doubled off its 52-week low of $1.72.
Summary
Shattuck reported a Q3 2026 net loss of $25.2 million as R&D jumped to $21.6 million, and said $196.3 million in cash funds operations into 2029. The company initiated its Phase 2b Crohn's trial of SL-325 and plans to start a Phase 2 HS trial in Q4 2026.
Key Events · Earnings and Guidance · STTK
-
Q3 Loss Widens on R&D Step-Up
Net loss was $25.2 million, or $0.14 per share, versus $10.1 million a year earlier, as R&D rose to $21.6 million from $7.6 million.
-
Cash Runway Extended Into 2029
Cash, equivalents and short-term investments totaled $196.3 million at September 30, 2026, up from $86.1 million a year earlier, funding operations into 2029.
-
Phase 2b Crohn's Trial Initiated
RECEPTIVE-CD1 randomizes approximately 232 patients 1:1:1:1 across three SL-325 dose levels and placebo, with endoscopic response at 12 weeks as the primary endpoint and data expected in the first half of 2028.
-
HS Phase 2 Planned for Q4 2026
RECEPTIVE-HS1 will test two dose levels versus placebo in approximately 150 patients with HiSCR50 at Week 16 as the primary endpoint; an IND was submitted in October 2026 and data are expected in the first half of 2028.
Analysis · STTK · Life Sciences
The quarterly loss widened sharply as R&D spending nearly tripled to $21.6 million, the cost of moving SL-325 into a 232-patient Phase 2b Crohn's trial and preparing a second Phase 2 in hidradenitis suppurativa. Against that burn, $196.3 million in cash and investments is expected to fund operations into 2029, so the spending increase is a deliberate pipeline build rather than a runway problem. The key read-through is timing: both SL-325 datasets land in the first half of 2028, leaving a long gap before the next major clinical catalyst.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STTK was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $516.9M. The 52-week trading range was $1.72 to $8.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.